A Phase 2a, randomized, placebo-controlled, dose-ranging study to evaluate the safety and efficacy of PTC518 in subjects with Huntington's disease
Latest Information Update: 24 Jun 2024
At a glance
- Drugs PTC 518 (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms PIVOT-HD
- Sponsors PTC Therapeutics
- 20 Jun 2024 According to a PTC Therapeutics media release, based on interim results from this trial the FDA lifts PTC518 partial clinical hold. The company will hold a conference call at 8:00 am EDT today to discuss this news.
- 20 Jun 2024 Interim results published in the PTC Therapeutics Media Release.
- 08 Jan 2024 According to a PTC Therapeutics media release, Results from 12-month interim data from the PIVOT-HD trial of PTC518 in HD patients are expected in the second quarter 2024.